Tether backs AIsa as strategic investor, completing seed extension round
AIsa said it had completed its seed extension round, with Tether and HIVEN joining as strategic investors.
The round brings AIsa’s total funding to more than $9 million. The two new investors joined Alibaba, Tribe Capital, Sumitomo Corporation, Draper Associates, Saison Capital and other backers.
“Enterprise AI agents need trusted information, useful tools and a governed way to transact,” said Jordan Liu, founder and CEO of San Francisco-based AIsa, in a Friday statement. “Our vision is to build the infrastructure that enables agents to discover, access and pay for resources globally, while giving enterprises full control over permissions, spending and transactions. We are excited to welcome Tether and HIVEN as strategic investors as we accelerate the transition from AI assistants to autonomous, production-ready agents.”
Fragmented providers, integrations and billing systems make it difficult for enterprise AI agents to operate effectively in production and manage at scale, according to the statement.
AIsa addresses this by bringing resource discovery, access and transactions into one governed, usage-based network, the Trusted Resource and Transaction Network for Enterprise AI Agents. Its infrastructure connects enterprise agents to external data, AI search, models, APIs, software tools and industry services, combining governed access with usage metering, billing and settlement, the
statement said.
Cointelegraph reported on July 31 that stablecoin issuer Tether generated another multibillion-dollar quarter as income from its US Treasury portfolio continued to bolster earnings.
Tether reported a net operating profit of $1.5 billion for the second quarter, driven primarily by interest earned on US Treasury holdings and repurchase agreements, or short-term loans backed by government securities.
Magazine: Capital starting to rotate back to crypto from AI: Raoul Pal
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why Snap Needed an Iron Man Star Before Its $2,195 Glasses Go on Sale

Profit surges; amid concerns over U.S. surgical volume, JPMorgan maintains "Overweight" on Intuitive Surgical (ISRG.US) and raises target price to $475
Intuitive Surgical (ISRG.US), the global leader in surgical robots, released its Q3 2026 earnings report on October 20 (U.S. Eastern Time). On the same day, JPMorgan published a research report, maintaining an "Overweight" rating on the stock.
Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) sets IPO price at $16-18 per share, plans to raise $250 million
Lycia Therapeutics announced the terms of its initial public offering (IPO) on Tuesday.
Dow Jones Top Markets Headlines at 3 AM ET: Asian Stocks Mixed as AI Spending Concerns Linger | U.S. ...
